Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.8123
-0.0006 (-0.07%)
Dec 12, 2025, 4:00 PM EST - Market closed
Biofrontera Revenue
Biofrontera had revenue of $6.99M in the quarter ending September 30, 2025, a decrease of -22.46%. This brings the company's revenue in the last twelve months to $37.16M, up 5.11% year-over-year. In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth.
Revenue (ttm)
$37.16M
Revenue Growth
+5.11%
P/S Ratio
0.20
Revenue / Employee
$399,613
Employees
93
Market Cap
9.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BFRI News
- 10 days ago - Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities - GlobeNewsWire
- 12 days ago - Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG - GlobeNewsWire
- 2 months ago - Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewsWire